Evidence map›Paper›PMID 36890858›Full record

ArticleCancer research communications2023

Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.

Shaaron Ochoa-Rios, Calvin R K Blaschke, Mengjun Wang, Kendell D Peterson, Andrew DelaCourt, Stéphane Elie Grauzam, David Lewin, Peggi Angel, Lewis R Roberts, Richard Drake and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shaaron Ochoa-RiosDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-0091-2355
Calvin R K BlaschkeDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-3988-6817
Mengjun WangDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-3001-3569
Kendell D PetersonDepartment of Pediatrics, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-9151-1188
Andrew DelaCourtDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-0280-1445
Stéphane Elie GrauzamDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-7524-258X
David LewinDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-0531-6018
Peggi AngelDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-4436-555X
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-7885-8574
Richard DrakeDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-6285-6440
Anand S MehtaDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-9846-9389
Medical University of South Carolina · USMayo Clinic · US

Funding

Predicting HCC through GlycomicsR01CA120206 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHTA, ANAND S. · 2006 to 2016
$4.3M
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Glycopathology of HCC: identification of the source cells of serum fucosylationU01CA226052 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DRAKE, RICHARD R., HOSHIDA, YUJIN · 2019 to 2023
$2.8M
Molecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6M
Translation of a biomarker panel for the early detection of hepatocellular carcinomaR01CA237659 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MARRERO, JORGE A, MEHTA, ANAND S. · 2019 to 2023
$2.5M
Aberrantly secreted glycoproteins as markers of liver cancerU01CA168856 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHTA, ANAND S. · 2012 to 2016
$1.5M
NCI NIH HHS R01 CA120206NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA237659NCI NIH HHS U01 CA168856NCI NIH HHS U01 CA226052NIDDK NIH HHS R01 DK099558
6 · The paper itself

Abstract

There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort ( Significance: This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsBile Ducts, IntrahepaticBiomarkersHumansBiomarkers

Identifiers

PMID36890858
PMCPMC9987250
OpenAlexW4320485848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.